PTC Therapeutics | PTCT - Gross Profit On Sales

Stock Price
73.10
Daily Change
0.74 1.02%
Monthly
-5.36%
Yearly
47.77%
Q1 Forecast
73.20

PTC Therapeutics reported $187.69M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
TG Therapeutics USD 133.62M 11.41M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025
Xencor USD 21M 22.61M Sep/2025